Cargando…
Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations
Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic treatment options for this relatively rare disease. Traditional cytotoxic agents, such as anthracyclines, alkylating agents, and taxanes have limited clinical benefi...
Autores principales: | In, Gino K., Hu, James S., Tseng, William W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524246/ https://www.ncbi.nlm.nih.gov/pubmed/28794805 http://dx.doi.org/10.1177/1758834017712963 |
Ejemplares similares
-
Impact of sarcopenia in advanced and metastatic soft tissue sarcoma
por: Strassmann, Dennis, et al.
Publicado: (2021) -
Treatment Strategies for Metastatic Soft Tissue Sarcomas
por: Wiltink, Lisette M., et al.
Publicado: (2021) -
Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Yuan, Jin, et al.
Publicado: (2021) -
Emollient treatment of atopic dermatitis: latest evidence and clinical considerations
por: Hon, Kam Lun, et al.
Publicado: (2018) -
Epidemiology, Treatment Patterns, and Outcomes of Metastatic Soft Tissue Sarcoma in a Community-Based Oncology Network
por: Chen, Clara, et al.
Publicado: (2014)